Clinical Policy: Gemcitabine Intravesical System (Inlexzo)
Customize your policy alerts
Sign up for mhn Policy CP.PHAR.753 alerts
Get alerted when Policy CP.PHAR.753 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity and prior authorization criteria for Inlexzo (gemcitabine intravesical system) for treatment of BCG-unresponsive non-muscle invasive bladder cancer and related coverage rules for affected members and providers.
Provider attestation that Adstiladrin® therapy has been considered and not recommended (provider must submit clinical rationale supporting use of Inlexzo over Adstiladrin) is required.
HCPCS code J9183 (Gemcitabine intravesical system, 225 mg) was added and codes J3590 and C9399 were removed.
ICHRA (health insurance marketplace/ICHRA) line of business was added to the policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.